SG11202009919WA - Process for preparing modulators of p300 and/or cbp - Google Patents
Process for preparing modulators of p300 and/or cbpInfo
- Publication number
- SG11202009919WA SG11202009919WA SG11202009919WA SG11202009919WA SG11202009919WA SG 11202009919W A SG11202009919W A SG 11202009919WA SG 11202009919W A SG11202009919W A SG 11202009919WA SG 11202009919W A SG11202009919W A SG 11202009919WA SG 11202009919W A SG11202009919W A SG 11202009919WA
- Authority
- SG
- Singapore
- Prior art keywords
- cbp
- modulators
- preparing
- preparing modulators
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Crushing And Grinding (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1806320.6A GB201806320D0 (en) | 2018-04-18 | 2018-04-18 | Process |
| PCT/GB2019/051110 WO2019202332A1 (en) | 2018-04-18 | 2019-04-18 | Process for preparing modulators of p300 and/or cbp |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202009919WA true SG11202009919WA (en) | 2020-11-27 |
Family
ID=62203477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202009919WA SG11202009919WA (en) | 2018-04-18 | 2019-04-18 | Process for preparing modulators of p300 and/or cbp |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11453662B2 (en) |
| EP (1) | EP3781562A1 (en) |
| JP (1) | JP7371006B2 (en) |
| KR (1) | KR20210003175A (en) |
| CN (1) | CN112351982A (en) |
| AU (1) | AU2019256788B2 (en) |
| BR (1) | BR112020021224A2 (en) |
| CA (1) | CA3096441A1 (en) |
| EA (1) | EA202092113A1 (en) |
| GB (1) | GB201806320D0 (en) |
| IL (1) | IL278015B2 (en) |
| MX (1) | MX2020010817A (en) |
| SG (1) | SG11202009919WA (en) |
| WO (1) | WO2019202332A1 (en) |
| ZA (1) | ZA202006441B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112574178A (en) * | 2019-09-27 | 2021-03-30 | 海创药业股份有限公司 | Deuterated benzimidazole compound and application thereof as EP300/CBP inhibitor |
| WO2021260111A1 (en) | 2020-06-25 | 2021-12-30 | Tolremo Therapeutics Ag | Combination of a cbp/p300 bromodomain inhibitor and a kras inhibitor for the treatment of cancer |
| CA3183982A1 (en) | 2020-06-25 | 2021-12-30 | Stefanie Fluckiger-Mangual | A combination of a cbp/p300 bromodomain inhibitor and an egfr inhibitor for use in treating egfr-mutant nsclc |
| KR20220101305A (en) | 2021-01-11 | 2022-07-19 | 주식회사 엘지에너지솔루션 | Battery module and battery pack including the same |
| CN114989158A (en) * | 2021-03-02 | 2022-09-02 | 复旦大学 | Histone acetyltransferase p300 bromodomain inhibitor, pharmaceutical composition thereof and application thereof |
| EP4257130A1 (en) * | 2022-04-08 | 2023-10-11 | Justus-Liebig-Universität Gießen | Inobrodib for use in the treatment of pulmonary arterial hypertension |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ104795A3 (en) | 1994-04-29 | 1996-02-14 | Lilly Co Eli | Benzimidazole derivative, process of its preparation, its use for preparing a pharmaceutical preparation and the pharmaceutical composition containing thereof |
| ATE253915T1 (en) | 1999-06-30 | 2003-11-15 | Merck & Co Inc | SRC KINASE INHIBITING COMPOUNDS |
| WO2002028839A1 (en) | 2000-10-06 | 2002-04-11 | Neurogen Corporation | Benzimidazole and indole derivatives as crf receptor modulators |
| US6951848B2 (en) | 2001-03-12 | 2005-10-04 | Millennium Pharmaceuticals, Inc., | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor |
| EP1490058B1 (en) | 2002-02-21 | 2007-10-10 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
| WO2004063151A2 (en) | 2003-01-03 | 2004-07-29 | Bristol-Myers Squibb Company | Novel tyrosine kinase inhibitors |
| US7312215B2 (en) | 2003-07-29 | 2007-12-25 | Bristol-Myers Squibb Company | Benzimidazole C-2 heterocycles as kinase inhibitors |
| WO2005118555A1 (en) | 2004-06-04 | 2005-12-15 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| WO2006124780A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase |
| WO2006136823A1 (en) | 2005-06-21 | 2006-12-28 | Astex Therapeutics Limited | Heterocyclic containing amines as kinase b inhibitors |
| EP1878724A1 (en) | 2006-07-15 | 2008-01-16 | sanofi-aventis | A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles |
| JP2010511721A (en) | 2006-12-05 | 2010-04-15 | ナショナル チャオ トン ユニバーシティ | Indazole compound |
| WO2009000413A1 (en) | 2007-06-26 | 2008-12-31 | Sanofi-Aventis | A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles |
| BRPI0814939A2 (en) | 2007-08-10 | 2015-01-27 | Glaxosmithkline Llc | CHEMICAL ENTITY, PHARMACEUTICAL COMPOSITION, AND METHOD FOR TREATING A VIRAL INFECTION IN A MAMMALIAN. |
| US20110052562A1 (en) | 2007-12-19 | 2011-03-03 | The Scripps Research Institute | Benzimidazoles and analogs as rho kinase inhibitors |
| US8501957B2 (en) | 2008-12-10 | 2013-08-06 | China Medical University | Benzimidazole compounds and their use as anticancer agents |
| WO2010068287A2 (en) | 2008-12-11 | 2010-06-17 | Angion Biomedica Corp. | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| US20120040916A1 (en) | 2008-12-22 | 2012-02-16 | Massachusetts Institute Of Technology | Molecular inhibitors of the wnt/beta-catenin pathway |
| WO2011045415A2 (en) | 2009-10-15 | 2011-04-21 | Guerbet | New imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases |
| US8455516B2 (en) | 2010-01-15 | 2013-06-04 | Touro University | HIV-1 fusion inhibitors and methods |
| WO2011097607A1 (en) | 2010-02-08 | 2011-08-11 | Southern Research Institute | Anti-viral treatment and assay to screen for anti-viral agent |
| AU2011253143A1 (en) | 2010-05-13 | 2012-12-06 | Amgen Inc. | Nitrogen- heterocyclic compounds as phosphodiesterase 10 inhibitors |
| EP2397471A1 (en) | 2010-06-16 | 2011-12-21 | China Medical University | Benzimidazole compounds and their use |
| JP5850503B2 (en) | 2010-09-14 | 2016-02-03 | 北海道公立大学法人 札幌医科大学 | Composition for treating muscular dystrophy |
| CN103476767B (en) | 2011-02-09 | 2015-06-10 | 弗·哈夫曼-拉罗切有限公司 | Heterocyclic compounds as PI3 kinase inhibitors |
| WO2012116440A1 (en) | 2011-03-03 | 2012-09-07 | Zalicus Pharmaceuticals Ltd. | Benzimidazole inhibitors of the sodium channel |
| JP2014114212A (en) | 2011-03-29 | 2014-06-26 | Dainippon Sumitomo Pharma Co Ltd | New benzimidazole derivative |
| TW201348231A (en) | 2012-02-29 | 2013-12-01 | Amgen Inc | Heterobicyclic compounds |
| EP2858983B1 (en) | 2012-06-11 | 2018-04-18 | UCB Biopharma SPRL | Tnf-alpha modulating benzimidazoles |
| AU2013289938A1 (en) | 2012-07-13 | 2015-01-29 | Indiana University Research & Technology Corporation | Compounds for treatment of spinal muscular atrophy |
| JP2016000697A (en) | 2012-10-02 | 2016-01-07 | 大日本住友製薬株式会社 | Pyrimidine derivative |
| JP2014073982A (en) | 2012-10-03 | 2014-04-24 | Dainippon Sumitomo Pharma Co Ltd | Pharmaceutical containing novel benzimidazole derivative |
| WO2014078479A2 (en) | 2012-11-14 | 2014-05-22 | The Board Of Regents Of The University Of Texas System | INHIBITION OF HIF-2α HETERODIMERIZATION WITH HIF1β (ARNT) |
| WO2014157382A1 (en) | 2013-03-29 | 2014-10-02 | 味の素株式会社 | Sphingosine kinase inhibitor |
| PL231063B1 (en) | 2013-04-10 | 2019-01-31 | Oncoarendi Therapeutics Spolka Z Ograniczona Odpowiedzialnoscia | Derivatives of 1-(substituted sulfonyl) 2-aminoimidazoline as an anticancer and antiproliferative agents |
| TWI527811B (en) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | Benzimidazole derivatives as bromodomain inhibitors |
| US9636328B2 (en) | 2013-06-21 | 2017-05-02 | Zenith Epigenetics Ltd. | Substituted bicyclic compounds as bromodomain inhibitors |
| WO2015023958A1 (en) | 2013-08-15 | 2015-02-19 | The University Of Kansas | Toll-like receptor agonists |
| GB201321741D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| KR102494596B1 (en) | 2014-07-31 | 2023-01-31 | 재단법인 한국파스퇴르연구소 | 2-amino-benzimidazole derivatives and their use as 5-lipoxygenase and/or prostaglandin e synthase inhibitors |
| JP6771464B2 (en) | 2014-11-27 | 2020-10-21 | ジェネンテック， インコーポレイテッド | 4,5,6,7-Tetrahydro-1H-pyrazolo [4,3-C] Pyridine-3-amine compound as CBP and / or EP300 inhibitor |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| EP3307798B2 (en) | 2015-06-12 | 2024-06-05 | Transitions Optical, Inc. | Alignment compounds |
| EP3334719B1 (en) | 2015-08-12 | 2021-09-15 | Neomed Institute | Substituted benzimidazoles, their preparation and their use as pharmaceuticals |
| EP3355871A1 (en) | 2015-10-02 | 2018-08-08 | Gilead Sciences, Inc. | Combinations of the btk inhibitor gs-4059 with inhibitors selected from a jak, ask1, brd and/or mmp9 inhibitor to treat cancer, allergic disorders, autoimmune diseases or inflammatory diseases |
| WO2017100525A1 (en) | 2015-12-11 | 2017-06-15 | The Board Of Regents Of The University Of Texas System | Substituted benzimidazolium, pyrido-imidazolium, or pyrazino-imidazolium compounds as chemotherapeutics |
| WO2017106568A1 (en) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combination of a jak inhibitor and a bromodomain inhibitor for treating cancer |
| CN109640988A (en) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | CXCR4 inhibitor and application thereof |
| EP3472129A4 (en) | 2016-06-21 | 2019-12-04 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| GB201617630D0 (en) * | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| US20180179191A1 (en) | 2016-11-22 | 2018-06-28 | Gilead Sciences, Inc. | Synthesis of a compound that modulates the activity of bromodomain-containing proteins |
-
2018
- 2018-04-18 GB GBGB1806320.6A patent/GB201806320D0/en not_active Ceased
-
2019
- 2019-04-18 US US17/047,178 patent/US11453662B2/en active Active
- 2019-04-18 MX MX2020010817A patent/MX2020010817A/en unknown
- 2019-04-18 SG SG11202009919WA patent/SG11202009919WA/en unknown
- 2019-04-18 CA CA3096441A patent/CA3096441A1/en active Pending
- 2019-04-18 CN CN201980033905.XA patent/CN112351982A/en active Pending
- 2019-04-18 BR BR112020021224-5A patent/BR112020021224A2/en unknown
- 2019-04-18 AU AU2019256788A patent/AU2019256788B2/en active Active
- 2019-04-18 JP JP2020556935A patent/JP7371006B2/en active Active
- 2019-04-18 EA EA202092113A patent/EA202092113A1/en unknown
- 2019-04-18 WO PCT/GB2019/051110 patent/WO2019202332A1/en unknown
- 2019-04-18 KR KR1020207033128A patent/KR20210003175A/en unknown
- 2019-04-18 EP EP19719605.8A patent/EP3781562A1/en active Pending
-
2020
- 2020-10-13 IL IL278015A patent/IL278015B2/en unknown
- 2020-10-16 ZA ZA2020/06441A patent/ZA202006441B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019202332A1 (en) | 2019-10-24 |
| EA202092113A1 (en) | 2021-03-30 |
| JP7371006B2 (en) | 2023-10-30 |
| BR112020021224A2 (en) | 2021-02-23 |
| ZA202006441B (en) | 2023-01-25 |
| CA3096441A1 (en) | 2019-10-24 |
| MX2020010817A (en) | 2020-10-28 |
| EP3781562A1 (en) | 2021-02-24 |
| AU2019256788A1 (en) | 2020-10-29 |
| KR20210003175A (en) | 2021-01-11 |
| US20210163463A1 (en) | 2021-06-03 |
| CN112351982A (en) | 2021-02-09 |
| JP2021521237A (en) | 2021-08-26 |
| IL278015A (en) | 2020-11-30 |
| US11453662B2 (en) | 2022-09-27 |
| GB201806320D0 (en) | 2018-05-30 |
| IL278015B1 (en) | 2023-04-01 |
| AU2019256788B2 (en) | 2022-10-20 |
| IL278015B2 (en) | 2023-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202006441B (en) | Process for preparing modulators of p300 and/or cbp | |
| IL287720A (en) | Modulators of thr-beta and methods of use thereof | |
| IL271149A (en) | Compounds for modulating s1p1 activity and methods of using the same | |
| EP3724188C0 (en) | Progranulin modulators and methods of using the same | |
| EP3723899A4 (en) | Filter aids for treating oil and methods of preparation and use thereof | |
| EP3568188A4 (en) | Catheter associated apparatus and methods of making and using same | |
| ZA202101214B (en) | Process and intermediates for the preparation of bilastine | |
| ZA202003590B (en) | Process for the preparation of opicapone and intermediates thereof | |
| IL273890A (en) | Process for preparing intermediate of anti-tumor drug niraparib and intermediate thereof | |
| IL290185A (en) | Solid state forms of risdiplam and process for preparation thereof | |
| IL283281A (en) | Formulation of contrast media and process of preparation thereof | |
| IL283201A (en) | Process and compounds for preparation of cannabinoids | |
| EP4061352A4 (en) | Compounds and methods of preparing compounds s1p1 modulators | |
| ZA202104403B (en) | Tablet and method of preparing same | |
| ZA201907515B (en) | Process for the preparation of pirlindole enantiomers and its salts | |
| FI4073051T3 (en) | Process and intermediate for the preparation of oxetan-2-ylmethanamine | |
| EP3849663C0 (en) | Pyrimidinyl-heteroaryloxy-naphthyl compounds and methods of use | |
| GB201805392D0 (en) | Methods of manufacture and associated apparatus | |
| PL3612535T3 (en) | Process for the preparation of pirlindole enantiomers and its salts | |
| RS62667B1 (en) | Process for the preparation of pirlindole enantiomers and its salts | |
| IL257193A (en) | Hommus making apparatus for home use and methods of use thereof | |
| GB201814328D0 (en) | Filter material and methods of forming filter material | |
| GB201719975D0 (en) | Filter apparatus and method of use thereof | |
| GB201716629D0 (en) | Filter apparatus and method of use thereof | |
| AU2017900267A0 (en) | Security apparatus and method of use |